Concert Bio Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Concert Bio Ltd. - overview
Established
2022
Location
London, -, UK
Primary Industry
Biotechnology
About
Based in London, UK, and founded by Paul Rutten (CEO) in 2022, Concert Bio Ltd operates as a biotechnology company that provides a platform to optimize microbial communities in biotech enterprises. In July 2022, the firm raised USD 1. 7 million in pre-seed funding led by investor The Venture Collective, with participation from other investors Nucleus Capital, Ponderosa Ventures, TET Ventures, etc. The company specializes in optimizing microbial ecosystems for businesses, particularly in soilless agriculture.
Concert Bio offers a platform integrating sampling equipment, microbial analysis via next-generation sequencing, and tailored interventions like probiotics. This approach offers monitoring solutions as well as actively improves microbial health by fostering beneficial communities crucial for plant growth and productivity. Concert Bio utilizes microbial ecology, molecular biology, and machine learning to offer precise insights into microbial ecosystems.
Current Investors
Day One Ventures, The Venture Collective, Nucleus Capital
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Medical Software, Analytics & Performance Software
Website
www.concert.bio
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.